Cleared Traditional

IMMUCHEM COVALENT COAT SOLID PHASE ASSAY (K791664) - FDA 510(k) Clearance

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K791664 · Immuchem Corp. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1979
Decision
37d
Days
Class 2
Risk

K791664 is an FDA 510(k) clearance for the IMMUCHEM COVALENT COAT SOLID PHASE ASSAY. Classified as Radioimmunoassay, Total Thyroxine (product code CDX), Class II - Special Controls.

Submitted by Immuchem Corp. (Mchenry, US). The FDA issued a Cleared decision on September 27, 1979 after a review of 37 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1700 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Immuchem Corp. devices

Submission Details

510(k) Number K791664 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 21, 1979
Decision Date September 27, 1979
Days to Decision 37 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
51d faster than avg
Panel avg: 88d · This submission: 37d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CDX Radioimmunoassay, Total Thyroxine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1700
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CDX Radioimmunoassay, Total Thyroxine

All 28
Devices cleared under the same product code (CDX) and FDA review panel - the closest regulatory comparables to K791664.
COAT-A-COUNT T4 RIA KIT
K811315 · Diagnostic Products Corp. · May 1981
RIA PHASE T4
K800203 · Boehringer Mannheim Corp. · Mar 1980
TETRABEAD - 125 T4 SOLID PHASE DIAG. KIT
K792188 · Abbott Laboratories · Nov 1979
QUANTIMUNE T-4 FIA
K790576 · Bio-Rad · Jul 1979
MICRO THYROXINE REAGENT SYSTEM
K781182 · Bd Becton Dickinson Vacutainer Systems Preanalytic · Aug 1978
EMIT CENTRIFICHEM THYROXINE ASSAY
K780639 · Syva Co. · May 1978